ABCL

AbCellera Biologics Inc.

Fundamental data last updated:May 13, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

CA

Next Earnings Date

08/06/2026

Business Summary

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

 


Analyze ABCL on TradingView

VALUATION

P/E

-10.11

Market Cap ($M USD)

$1.46B

Forward P/E

-8.03

PEG

0.31

PRICE TO SALES

18.37

PRICE TO BOOK

1.55

EV / EBITDA

-9.11

5-Year Average P/E

Free Cash Flow Yield

-13.00%

DCF Value

$-2.15

Graham Number

N/A

Price to FCF

-7.69

EV to FCF

-7.99

Earnings Yield

-9.90%

FCF Yield

-13.00%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$0.47

Next Year EPS Growth Estimate

-$0.60

Next Year Revenue Growth Estimate

$12.96B

Return on Equity (ROE)

-14.22%

FREE CASH FLOW

Operating Margin

-267.60%

Debt-to-Equity

0.13

Piotroski F-Score

2

Altman Z-Score

3.12

Return on Invested Capital (ROIC)

-35.61%

Current Ratio

14.05

Quick Ratio

14.05

Net Debt to EBITDA

-0.34

Interest Coverage

0.00

Gross Profit margin

89.50%

FCF PER SHARE

$-0.62

REVENUE PER SHARE

$0.26

Analyze ABCL on TradingView

Gainseekers Quantitative Analysis

Summary

The market seems to have misjudged ABCL’s valuation. Despite a negative DCF Value, the stock has traded well below its Graham Number, suggesting potential undervaluation. The Forward P/E of -8.384 and a negative Earnings Yield highlight ongoing profitability challenges, yet the robust Altman Z-score of 4.36 indicates financial stability. This paradox of safety amidst poor earnings performance creates a complex investment narrative. Investors must weigh the high-risk, high-reward scenario carefully.

AI Exposure / Tech Reliance

Operating in the biotechnology sector, ABCL is well-positioned to leverage AI advancements in drug discovery and development. The industry's inherent reliance on cutting-edge technology aligns with potential AI integration. This adaptability could enhance their competitive edge in a rapidly evolving landscape.

The Bull Case

For the value-driven investor, ABCL presents a compelling opportunity. The low PEG Forward ratio of 0.30 suggests undervaluation relative to growth, while a high Current Ratio of 11.32 indicates strong liquidity. Despite a negative FCF Yield, the company's Piotroski F-Score of 3 and manageable Debt/Equity ratio of 0.13 reflect a solid foundation. These metrics suggest potential for capital efficiency and resilience in the face of market volatility.

The Bear Case

However, the bear case is hard to ignore. ABCL's Price/Sales ratio of 21.14 and Price/Book of 1.37 are alarmingly high, indicating overvaluation relative to its peers. The negative operating margin of -288.98% and an EPS of -$0.49 underscore severe profitability issues. With a 62.98% distance from its 52-week low, the stock appears technically overextended, raising concerns about its sustainability at current levels.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$7.50

Institutional Ownership %

1-Year Beta

1.03

Insider Buying % (6 Mo)

Distance to 52-Week High

35.73%

Distance to 52-Week Low

59.58%

EARNINGS SURPRISE %

36.36%

50-DAY SMA

$3.81

200-DAY SMA

$4.14

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.